- Home
- IGMS vs IHD Comparison
IGMS vs IHD Comparison
Compare IGMS & IHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- IHD
- Stock Information
- Founded
- IGMS 1993
- IHD 2011
- Country
- IGMS United States
- IHD United States
- Employees
- IGMS N/A
- IHD N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- IHD Investment Managers
- Sector
- IGMS Health Care
- IHD Finance
- Exchange
- IGMS Nasdaq
- IHD Nasdaq
- Market Cap
- IGMS 82.1M
- IHD 89.7M
- IPO Year
- IGMS 2019
- IHD N/A
- Fundamental
- Price
- IGMS $1.38
- IHD $5.42
- Analyst Decision
- IGMS Hold
- IHD
- Analyst Count
- IGMS 8
- IHD 0
- Target Price
- IGMS $6.14
- IHD N/A
- AVG Volume (30 Days)
- IGMS 368.0K
- IHD 27.7K
- Earning Date
- IGMS 03-06-2025
- IHD 01-01-0001
- Dividend Yield
- IGMS N/A
- IHD 10.32%
- EPS Growth
- IGMS N/A
- IHD N/A
- EPS
- IGMS N/A
- IHD N/A
- Revenue
- IGMS $2,918,000.00
- IHD N/A
- Revenue This Year
- IGMS $26.85
- IHD N/A
- Revenue Next Year
- IGMS $125.17
- IHD N/A
- P/E Ratio
- IGMS N/A
- IHD N/A
- Revenue Growth
- IGMS 57.64
- IHD N/A
- 52 Week Low
- IGMS $1.26
- IHD $4.49
- 52 Week High
- IGMS $22.50
- IHD $5.47
- Technical
- Relative Strength Index (RSI)
- IGMS 26.21
- IHD 65.54
- Support Level
- IGMS $1.26
- IHD $5.11
- Resistance Level
- IGMS $1.54
- IHD $5.27
- Average True Range (ATR)
- IGMS 0.13
- IHD 0.07
- MACD
- IGMS 0.22
- IHD 0.03
- Stochastic Oscillator
- IGMS 29.27
- IHD 75.06
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.